leadf
logo-loader
viewA2 Milk Co Ltd.

a2 Milk Company signs deal with Fonterra, net profit surges 150%

Fonterra will build a pool of farmer-suppliers in New Zealand and Australia.

a2 milk packaging
a2’s share of fresh milk sales in Australia is now at 9.5%

a2 Milk Company Ltd (Australia) (ASX:A2M) has signed a joint marketing deal with dairy giant Fonterra Co-operative Group (NZE:FCG) focused on its a2 Milk®.

a2 Milk comes from cows selected to naturally produce only A2 protein and no A1 protein, which makes it easy to digest.

Under the new agreement, Fonterra will build a pool of farmer-suppliers in New Zealand and Australia, which will require genetic testing to identify the A2-producing cows.

The Fonterra-sourced A2 milk, butter and cheese may be sold in Australia, the U.S., UK and Southeast Asia.

The aim is to build greater returns for both companies by growing demand locally and internationally using A2 Milk Company's increasingly popular brand strength

Sale of infant formula in Australia and China is surging

Surging sales of infant formula in Australia and China have pushed the company's first-half net profit up by 150% to $88.8 million.

Investors lapped up the news sending a2's shares soaring upwards more than 25% intra-day to $10.89.

a2 Milk is also planning to enter the New Zealand fresh milk market for the first time.

a2 holds 30% share of the Australian infant formula market

The company’s share by value of the massive infant formula market in China had grown strongly in the first half of fiscal 2018, from 3.5% at the end of June 2017 to 5.4% at the end of December.

Significantly, a2’s share of the Australian infant formula market also grew strongly, with the company now holding a 30% market share in this country.

a2’s share of fresh milk sales in Australia is now at 9.5%.

READ: A2 Milk expands into North East region of the US, targeting 5000 stores by January

Quick facts: A2 Milk Co Ltd.

Price: 11.89 USD

OTCMKTS:ACOPF
Market: PINK
Market Cap: $8.81 billion
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Orthocell 'in exciting regulatory phase' as it looks to drive its...

Orthocell Ltd's (ASX:OCC) Paul Anderson says the company's in an exciting regulatory phase having validated its technologies in the clinic and defining pathways to market through the US FDA process. ''We have some significant milestones ahead of us - we have an application within the FDA at the...

18 hours, 7 minutes ago

2 min read